J9326 Telisotuzumab vedotin-tllv - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Telisotuzumab vedotin-tllv

Brand Name:

Emrelis

Strength:

1mg

HCPCS:

J9326

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

c-MET

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

Jan. 12, 2026

CMS Discontinuation Date:

Status:

In Use